Jonker, D. J., Laurie, S. A., Cote, G. M., Flaherty, K., Fuchs, C. S., Chugh, R., … Li, C. (2015). Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. In Journal of Clinical Oncology (Vol. 33, pp. 3615–3615). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.3615

Jonker, Derek J., Scott Andrew Laurie, Gregory Michael Cote, Keith Flaherty, Charles S. Fuchs, Rashmi Chugh, David C. Smith, et al. “Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.” In Journal of Clinical Oncology, 33:3615–3615. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.3615.

Jonker DJ, Laurie SA, Cote GM, Flaherty K, Fuchs CS, Chugh R, et al. Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3615–3615.

Jonker, Derek J., et al. “Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.” Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 3615–3615. Crossref, doi:10.1200/jco.2015.33.15_suppl.3615.

Jonker DJ, Laurie SA, Cote GM, Flaherty K, Fuchs CS, Chugh R, Smith DC, Edenfield WJ, Conkling PR, Mier JW, Goodwin RA, Kwak EL, Abrams TA, Goel R, Cleary JM, Li W, Li Y, Jemison J, Hitron M, Li C. Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 3615–3615.